Sulfonylureas and insulin treatment are known to be associated with weight gain (44), while GLP-1RA induce weight loss (45), which could explain the advantage of GLP-1RA over insulin-based therapies as treatment for NAFLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.